Key Points 1. This study reports clinical outcome data on 76 patients
with platinum-resistant recurrent or metastatic head and neck squamous
carcinoma treated with nivolumab, making it the largest published single
centre case series of its kind. 2. Radiotherapy was administered
alongside systemic therapy with nivolumab, defined as radiotherapy
within 8 weeks of prior systemic therapy, in 16 of 76 patients (21%).
3. Nivolumab was continued following radiotherapy completion due to
ongoing clinical benefit from the drug in 9 of 16 patients (56%). 4.
Durable complete response following radio-immunotherapy was seen in 2 of
the 9 patients (22%) who continued nivolumab subsequent to
radiotherapy. 5. Indications for radiotherapy included symptom control
(3 of 9), oligoprogression (5 of 9) and incomplete response (1 of 9).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.